NCT05745532View on ClinicalTrials.gov

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

May 30, 2025

Study Completion Date

December 30, 2025

Conditions
β-thalassemia
Interventions
BIOLOGICAL

β-globin restored autologous hematopoietic stem cells

β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q

Trial Locations (1)

518083

RECRUITING

Shenzhen Children's Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen Hemogen

INDUSTRY